Together, these data raise the hope that rational combination treatments targeting oncogenic HH/GLI and immunosuppressive mechanisms will synergistically improve the efficacy and durability of the therapeutic response of BCC patients with advanced or metastatic disease. Here, GLI1 is linked to skin basal cell carcinoma.